Recent Updates
Recently added Catalysts
NVAX

Novavax to Present at the Wedbush Securities Life Sciences Management Access Conference

Key Takeaway: GAITHERSBURG, Md., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Barclay "Buck" Phillips

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
SARS-CoV-2 rS/Matrix-M1 Adjuvant
Phase 3 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Barclay "Buck" Phillips, SVP, Chief Financial Officer and Treasurer, will present at the Wedbush Securities Life Sciences Management Access Conference to be held on Wednesday, August 13, 2014 at 3:40 pm ET in New York City at the Le Parker Meridien hotel.
A live webcast link for the presentation will be available via the company's website at www.novavax.com under Investor Info/Events.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.
Last updated: Aug 7, 2014